Tolerability, safety, and efficacy of ziprasidone (80-160 mg/d) versus olanzapine (10-20 mg/d), risperidone (4-8 mg/d) or quetiapine (300-750 mg/d) in pretreated patients with schizophrenia, schizoaffective disorder or schizophreniform disorders - a 12-week open-label, multicenter clinical trial

Trial Profile

Tolerability, safety, and efficacy of ziprasidone (80-160 mg/d) versus olanzapine (10-20 mg/d), risperidone (4-8 mg/d) or quetiapine (300-750 mg/d) in pretreated patients with schizophrenia, schizoaffective disorder or schizophreniform disorders - a 12-week open-label, multicenter clinical trial

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Jan 2008

At a glance

  • Drugs Olanzapine; Quetiapine; Risperidone; Ziprasidone
  • Indications Psychotic disorders; Schizoaffective disorder; Schizophrenia
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 29 Oct 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top